Burning Rock Biotech Limited (BNR)

Market Cap	88.17M
Revenue (ttm)	75.80M
Net Income (ttm)	-92.20M
Shares Out	107.42M
EPS (ttm)	-0.88
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18
Open	0.828
Previous Close	0.867
Day's Range	0.791 - 0.859
52-Week Range	0.572 - 3.250
Beta	0.23
Analysts	n/a
Price Target	n/a
Earnings Date	May 28, 2024

About BNR

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colo...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jun 12, 2020
• Employees: 1,138
• Stock Exchange: NASDAQ
• Ticker Symbol: BNR

Financial Performance

In 2023, BNR's revenue was 537.44 million, a decrease of -4.58% compared to the previous year's 563.24 million. Losses were -653.69 million, -32.69% less than in 2022.

Financial numbers in CNY